Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2021 | Management of immune-related adverse events in ICI therapy

Jeffrey Weber, MD, PhD, NYU Langone Medical Center, New York City, NY, outlines the new ASCO guidelines on the management of immune-related adverse events in patients treated with immune checkpoint inhibitor (ICI) therapy. ICI therapy should initially be closely monitored for Grade 1 toxicities except for some neurologic, hematologic, and cardiac toxicities, and should be suspended for most Grade 2 and 3 toxicities and started again when side effects revert to Grade 1. Whilst corticosteroids may be used, they should be gradually reduced over the course of 4-6 weeks and other alternative immunosuppressive therapies should be offered to steroid-refractory patients. ICIs should be permanently discontinued in patients experiencing Grade 4 toxicities. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

Disclosures

I consult for and have received less than $10,000 dollars per annum from Merck, Genentech, Astra Zeneca, GSK, Novartis, Nektar, Celldex, Incyte, Biond, ImCheck, Sellas, Evaxion and EMD Serono and $10-25,000 dollars from BMS for membership on Advisory Boards

I hold equity in Biond, Evaxion, Instil Bio, OncoC4 and Neximmune

I am on scientific advisory boards for Evaxion, ImCheck, Biond, Sellas, Instil Bio, OncoC4 and Neximmune and am remunerated between $10,000-$75,000 dollars

I am not a member of any speaker’s bureau

NYU, but not me personally, received research support from BMS, Merck, GSK, Moderna, Pfizer, Novartis and Astra Zeneca

Moffitt Cancer Center filed a patent on an IPILIMUMAB biomarker and on TIL preparation that I am named on, and Biodesix filed a PD-1 patent that I was named on; I receive less than $1500 yearly in royalties